IL280451B2 - A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation - Google Patents

A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation

Info

Publication number
IL280451B2
IL280451B2 IL280451A IL28045121A IL280451B2 IL 280451 B2 IL280451 B2 IL 280451B2 IL 280451 A IL280451 A IL 280451A IL 28045121 A IL28045121 A IL 28045121A IL 280451 B2 IL280451 B2 IL 280451B2
Authority
IL
Israel
Prior art keywords
pharmaceutical preparation
hematopoietic stem
stem cell
day
cell transplantation
Prior art date
Application number
IL280451A
Other languages
English (en)
Hebrew (he)
Other versions
IL280451B1 (en
IL280451A (en
Inventor
Corrado Claudia
Bucher Christoph
Jones Julie
Gergely Peter
Original Assignee
Priothera Ltd
Corrado Claudia
Bucher Christoph
Jones Julie
Gergely Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Ltd, Corrado Claudia, Bucher Christoph, Jones Julie, Gergely Peter filed Critical Priothera Ltd
Publication of IL280451A publication Critical patent/IL280451A/en
Publication of IL280451B1 publication Critical patent/IL280451B1/en
Publication of IL280451B2 publication Critical patent/IL280451B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL280451A 2018-07-27 2019-07-26 A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation IL280451B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018141411 2018-07-27
JP2019036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Publications (3)

Publication Number Publication Date
IL280451A IL280451A (en) 2021-03-25
IL280451B1 IL280451B1 (en) 2025-06-01
IL280451B2 true IL280451B2 (en) 2025-10-01

Family

ID=69181631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280451A IL280451B2 (en) 2018-07-27 2019-07-26 A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361506A1 (en) * 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
JP2016509050A (ja) * 2013-02-20 2016-03-24 ノバルティス アーゲー 移植患者における移植片対宿主病の治療
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
AU2009206733A1 (en) * 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361506A1 (en) * 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
JP2016509050A (ja) * 2013-02-20 2016-03-24 ノバルティス アーゲー 移植患者における移植片対宿主病の治療
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIAL NCT01830010:, A TWO-PART STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF KRP203 IN PATIENTS UNDERGOING STEM CELL TRANSPLANT FOR HEMATOLOGICAL MALIGNANCIES, 30 May 2018 (2018-05-30) *
GAUTHIER J. ET AL.:, SUCCESSFUL TREATMENT WITH FINGOLIMOD OF GRAFT-VERSUS-HOST DISEASE OF THE CENTRAL NERVOUS SYSTEM, 9 January 2018 (2018-01-09) *
MAWAD R. ET AL.:, STRATEGIES TO REDUCE RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA, 10 July 2013 (2013-07-10) *
WHITE C. ET AL.:, THE EMERGING ROLE OF FTY720 (FINGOLIMOD) IN CANCER TREATMENT, 26 April 2016 (2016-04-26) *

Also Published As

Publication number Publication date
MX2021001039A (es) 2021-04-12
KR102948053B1 (ko) 2026-04-06
CN112512516A (zh) 2021-03-16
WO2020022507A1 (ja) 2020-01-30
EP3831370A4 (en) 2022-04-27
IL280451B1 (en) 2025-06-01
BR112021001376A2 (pt) 2021-04-20
US20210283073A1 (en) 2021-09-16
TWI899057B (zh) 2025-10-01
JP7389486B2 (ja) 2023-11-30
KR20210040954A (ko) 2021-04-14
CA3106608A1 (en) 2020-01-30
TW202011948A (zh) 2020-04-01
AU2019311609A1 (en) 2021-02-04
CN120284929A (zh) 2025-07-11
AU2019311609B2 (en) 2024-09-26
EP3831370A1 (en) 2021-06-09
IL280451A (en) 2021-03-25
JPWO2020022507A1 (ja) 2021-08-05

Similar Documents

Publication Publication Date Title
Vose et al. Update on epidemiology and therapeutics for non-Hodgkin’s lymphoma
IL280451B2 (en) A preparation for preventing recurrence of proliferative blood disease in patients who have undergone hematopoietic stem cell transplantation
US12171778B2 (en) Methods of treating myelodysplastic syndrome
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
US12060332B2 (en) Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
CA3145391A1 (en) Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
Huang et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation
CA3106608C (en) Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
CN115120724A (zh) 治疗再生障碍性贫血的方法和药物组合物
Wright et al. The role of fludarabine in hematological malignancies
US8236811B2 (en) Therapeutic use for treating of leukemia
HK40050286A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
EA048825B1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток
US20260115223A1 (en) Methods of treating myelodysplastic syndrome
US20230416391A1 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patients
KR20140138885A (ko) 급성 골수성 백혈병 또는 만성 골수성 백혈병을 치료하기 위한 신규 조합물
WO2023234933A1 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patients
Watanabe et al. The synergistic effect of bactobolamine and tacrolimus on in vitro and in vivo experiments
Colleselli et al. THE ROLE OF AUTOLOGOUS BONE MARROW TRANSPLANTATION IN THE TREATMENT OF CHILDHOOD LYMPHOBLASTIC LEUKEMIA: Experience of the Italian Pediatric Study Group
HK40027129A (en) Methods of treating myelodysplastic syndrome